Transfer of natalizumab into breast milk in a mother with multiple sclerosis

J Hum Lact. 2015 May;31(2):233-6. doi: 10.1177/0890334414566237. Epub 2015 Jan 13.


Natalizumab (Tysabri) is a recombinant humanized antibody to α4-integrin that is approved by the Food and Drug Administration for the treatment of multiple sclerosis (MS) and Crohn disease. This is a case report of a 28-year-old woman with MS who was taking natalizumab (300 mg intravenously infused over 1 hour every 4 weeks) while breastfeeding her 11.5-month-old daughter 3 times a day. Breast milk samples were collected over a 50-day period after the patient's first drug infusion. The average concentration of natalizumab was 0.93 µg/mL/d, and the relative infant dose was 1.74% of the weight-adjusted maternal dose. Transfer of natalizumab into human milk increased over time and with subsequent injections, with the highest concentration of 2.83 µg/mL at day 50 with a relative infant dose of 5.3%. Because these data suggest continued accumulation of natalizumab in milk, and because we cannot provide an accurate assessment of levels of this drug at 24 weeks (steady state), we are unable to determine safety at this time.

Keywords: breast milk; breastfeeding; multiple sclerosis; natalizumab.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Breast Feeding*
  • Female
  • Humans
  • Immunologic Factors / administration & dosage*
  • Immunologic Factors / pharmacokinetics
  • Infant, Newborn
  • Infusions, Intravenous
  • Milk, Human / metabolism*
  • Multiple Sclerosis / drug therapy*
  • Natalizumab / administration & dosage*
  • Natalizumab / pharmacokinetics
  • Pregnancy


  • Immunologic Factors
  • Natalizumab